4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Scott Bizily Sells 4,248 Shares

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 4,248 shares of the stock in a transaction on Monday, July 1st. The shares were sold at an average price of $21.36, for a total value of $90,737.28. Following the completion of the transaction, the insider now directly owns 1,737 shares of the company’s stock, valued at $37,102.32. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Scott Bizily also recently made the following trade(s):

• On Thursday, May 16th, Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $25.45, for a total transaction of $44,537.50.
• On Tuesday, April 16th, Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $25.74, for a total transaction of $45,045.00.

4D Molecular Therapeutics Price Performance

Shares of FDMT opened at $21.15 on Friday. The firm has a 50-day simple moving average of $24.07 and a two-hundred day simple moving average of $24.81. 4D Molecular Therapeutics, Inc. has a 1-year low of $9.44 and a 1-year high of $36.25. The stock has a market cap of $1.09 billion, a PE ratio of -8.67 and a beta of 2.83.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Thursday, May 9th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.07. The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $1.44 million. As a group, sell-side analysts expect that 4D Molecular Therapeutics, Inc. will post -2.98 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on FDMT shares. Jefferies Financial Group increased their price objective on shares of 4D Molecular Therapeutics from $30.00 to $58.00 and gave the company a “buy” rating in a report on Monday, April 1st. Barclays began coverage on 4D Molecular Therapeutics in a report on Monday, April 15th. They issued an “overweight” rating for the company. HC Wainwright reissued a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Friday, June 7th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $40.00 target price on shares of 4D Molecular Therapeutics in a research note on Wednesday, June 26th. Finally, BMO Capital Markets lowered their price target on shares of 4D Molecular Therapeutics from $70.00 to $63.00 and set an “outperform” rating on the stock in a research report on Monday, April 1st. Ten research analysts have rated the stock with a buy rating, Based on data from MarketBeat, 4D Molecular Therapeutics currently has an average rating of “Buy” and an average target price of $45.63.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Daiwa Securities Group Inc. boosted its holdings in 4D Molecular Therapeutics by 23.3% during the 4th quarter. Daiwa Securities Group Inc. now owns 5,872 shares of the company’s stock valued at $119,000 after acquiring an additional 1,110 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of 4D Molecular Therapeutics by 6.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 23,952 shares of the company’s stock valued at $764,000 after purchasing an additional 1,356 shares during the period. Bfsg LLC acquired a new position in shares of 4D Molecular Therapeutics in the fourth quarter valued at approximately $30,000. Mirae Asset Global Investments Co. Ltd. increased its stake in 4D Molecular Therapeutics by 14.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,612 shares of the company’s stock worth $438,000 after buying an additional 2,700 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its stake in 4D Molecular Therapeutics by 702.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company’s stock worth $110,000 after buying an additional 3,026 shares during the period. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.